Human CD44 v6 Antibody (2F10)

R&D Systems | Catalog # BBA13

R&D Systems

Key Product Details

Validated by

Knockout/Knockdown

Species Reactivity

Validated:

Human

Cited:

Human, Mouse, Xenograft

Applications

Validated:

Immunohistochemistry, Western Blot, Flow Cytometry, Immunocytochemistry, Immunoprecipitation, CyTOF-ready

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, Neutralization, Flow Cytometry, Immunocytochemistry, Immunoprecipitation, Bioassay, ELISA Detection, Immunogold Electron Microscopy

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 2F10
Loading...

Product Specifications

Immunogen

Recombinant human CD44 v3-10

Specificity

Detects human CD44v6 in Western blots. By flow cytometry analysis using a panel of CD44-transfected COS cells (9), monoclonal antibody clone 2F10 was deduced to be specific for human CD44 protein isoforms containing variant exon 6 (CD44v6).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Scientific Data Images for Human CD44 v6 Antibody (2F10)

Detection of CD44 antibody in Human Blood Monocytes antibody by Flow Cytometry.

Detection of CD44 in Human Blood Monocytes by Flow Cytometry.

Human peripheral blood monocytes were stained with Mouse Anti-Human CD44 v6 Monoclonal Antibody (Catalog # BBA13, filled histogram) or isotype control antibody (MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B).

CD44 in A431 Human Cell Line.

CD44 was detected in immersion fixed A431 human epithelial carcinoma cell line (positive staining) and Daudi human Burkitt's lymphoma cell line (negative staining) using Mouse Anti-Human CD44 v6 Monoclonal Antibody (Catalog # BBA13) at 25 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; NL007) and counterstained with DAPI (blue). Specific staining was localized to cell surface. Staining was performed using our protocol for Fluorescent ICC Staining of Non-adherent Cells.
CD44 antibody in Human Colon Adenocarcinoma Tissue by Immunohistochemistry (IHC-P).

CD44 in Human Colon Adenocarcinoma Tissue.

CD44 was detected in immersion fixed paraffin-embedded sections of human colon adenocarcinoma tissue using Mouse Anti-Human CD44 v6 Monoclonal Antibody (Catalog # BBA13) at 1.7 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
Detection of Human CD44 by Immunohistochemistry

Detection of Human CD44 by Immunohistochemistry

Immunohistochemistry of candidate biomarkers in prostate cancer. Representative immunohistochemical staining of ACPP, ADAM9, ALDH1A2, CASR, CCND1, CCPG1, CD34, CD44, CD44v6, CHGA, CHMP1A, EI24, ENO2, GADD45B, HA, HAS2, HES6, HMMR, HOXC6, HYAL1, IGF1, IQCK, MAP4K4, MKI67, PAGE4, PLIN2, PTEN, SIAH2, SMAD4, SOX9, SPP1, SYP, and TP53 from prostate cancer tissue microarrays. Scale bar represents 50 μm. Image collected and cropped by CiteAb from the following publication (https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-14-244), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human CD44 by Immunohistochemistry

Detection of Human CD44 by Immunohistochemistry

Immunochemical staining of selected biomarkers in early gastric cancer tissues.(A) E-cadherin (B) a1 catenin (C) p53 (D) EZH (E) CD44v6. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0159424), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human CD44 by Western Blot

Detection of Human CD44 by Western Blot

Knockdown of CD44v6 with siRNA transfection in YCC-2 cell line and overexpression of CD44v6 with plasmid transfection in MKN-28 cell line. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0159424), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44v6 by Western Blot

Detection of CD44v6 by Western Blot

A-B Expression of CD44st, CD44s, CD44v6 mRNA and miR-138-5p in breast cancer cell lines. A Semi-quantitative PCR agarose electrophoresis plots of different cell lines B Quantitative PCR results of different cell lines Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36964570), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44v6 by Western Blot

Detection of CD44v6 by Western Blot

A-B Expression of CD44st, CD44s, CD44v6 mRNA and miR-138-5p in breast cancer cell lines. A Semi-quantitative PCR agarose electrophoresis plots of different cell lines B Quantitative PCR results of different cell lines Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36964570), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

CD44v6 suppression reduces the invasive behavior of endocrine-resistant breast cancer cells. (A,B) siRNA suppression reduced CD44v6 expression in Tam-R and Fas-R cells without altering the expression of other CD44 variant isoforms. CD44v6 suppression in Tam-R cells reduced their invasive (C) and proliferative (D) capacity and enhanced their migration (E) whereas modest suppression of proliferation and migration was seen in Fas-R cells. (F) Western blotting analysis revealed that CD44v6 suppression reduced EGFR pathway component activity in Tam-R cells and suppressed Met and AKT signaling in Fas-R cells but did not alter total protein levels (F). Image collected and cropped by CiteAb from the following open publication (http://journal.frontiersin.org/Article/10.3389/fonc.2016.00145/abstract), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

CD44v6 expression is associated with the migration and invasion of breast cancer. (A) Expression of CD44v6 in the breast cancer cell lines MCF-7, T-47D, Hs-578t, and BT-549. Left, western blot analysis of CD44v6 protein; Right, qRT-PCR analysis of CD44v6 mRNA levels.(B) Immunoblot analysis of CD44v6 expression in Hs-578t and BT-549 cells transfected with CD44v6 siRNA. (C-D) Migration (left, wound healing) and invasion (right, transwell) assays for control and CD44v6 knockdown Hs-578t (upper panel) and BT-549 (bottom panel) cells. Quantitative results of migratory cells are shown. Data show the mean±SD of three independent experiments. **P<0.01;***P<0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31892992), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

DAB2 favorably sequesters a CD44v6-LRP6 complex in the direction of clathrin-dependent endocytosis to retain FOLFOX sensitivity. (A), mRNA expressions of disheveled protein 2 (DVL-2) and DAB2 protein normalized to beta -actin in sensitive and resistant pairs of cells are shown by qPCR. (B), Whole cell lysates (WCL) of Vector and DAB2 cDNA transfected SW480-FR cells at time 0 or after 12 hours treatment with or without WNT3A were analyzed by WB for the indicated proteins. Vector (C), and DAB2 cDNA (D) transfected SW480-FR cells were treated with or without WNT3A for 12 hours, and the Triton X-100 (1%) insoluble fractions were separated into lipid raft (R) and non-raft (NR) by OptiPrep gradient centrifugation. Pooled OptiPrep gradient fractions (light fractions (3–4) and non-raft heavy fractions (7–8)) were immunoprecipitated with anti-caveolin-1 (left panels) and anti-clathrin (right panels) antibodies. Immunocomplexes were immunoblotted for CD44v6, LRP6 (S1490), LRP6, Axin, GSK3 beta, and DAB2, and for clathrin or caveolin (bottom panels). IgG antiserum was used as negative control for the various immunoprecipitations. QPCR data represent results from 3 independent experiments done in n = 3-6 replicates. All WB data are representative of 4 independent experiments. (A), *P < 0.05 was considered significant, DVL2 and Dab2 mRNA expressions in FR cells were compared with S cells. (B), *P < 0.05 was considered significant, DVL2 and Dab2 mRNA expressions in LGK974 treated SW480-FR cells were compared with untreated SW480-FR cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36330477), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

miR-193b-5p inhibits the migration and invasion of breast cancer cells triggered by CD44v6 (A, B) miR-193b-5p inhibited the migration (A) and invasion (B) of Hs-578t and BT-549 cells, whereas CD44v6 overexpression abolished these changes. Quantitative results of migratory cells are shown on the right,*P<0.05; **P<0.01; ***P <0.001. (C) Protein levels of CD44v6 and CD44s in Hs-578t (left) and BT-549 (right) cells overexpressing miR-193b-5p mimic and CD44v6. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31892992), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

DAB2 favorably sequesters a CD44v6-LRP6 complex in the direction of clathrin-dependent endocytosis to retain FOLFOX sensitivity. (A), mRNA expressions of disheveled protein 2 (DVL-2) and DAB2 protein normalized to beta -actin in sensitive and resistant pairs of cells are shown by qPCR. (B), Whole cell lysates (WCL) of Vector and DAB2 cDNA transfected SW480-FR cells at time 0 or after 12 hours treatment with or without WNT3A were analyzed by WB for the indicated proteins. Vector (C), and DAB2 cDNA (D) transfected SW480-FR cells were treated with or without WNT3A for 12 hours, and the Triton X-100 (1%) insoluble fractions were separated into lipid raft (R) and non-raft (NR) by OptiPrep gradient centrifugation. Pooled OptiPrep gradient fractions (light fractions (3–4) and non-raft heavy fractions (7–8)) were immunoprecipitated with anti-caveolin-1 (left panels) and anti-clathrin (right panels) antibodies. Immunocomplexes were immunoblotted for CD44v6, LRP6 (S1490), LRP6, Axin, GSK3 beta, and DAB2, and for clathrin or caveolin (bottom panels). IgG antiserum was used as negative control for the various immunoprecipitations. QPCR data represent results from 3 independent experiments done in n = 3-6 replicates. All WB data are representative of 4 independent experiments. (A), *P < 0.05 was considered significant, DVL2 and Dab2 mRNA expressions in FR cells were compared with S cells. (B), *P < 0.05 was considered significant, DVL2 and Dab2 mRNA expressions in LGK974 treated SW480-FR cells were compared with untreated SW480-FR cells. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36330477), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

miR-193b-5p targets CD44v6 via a regulatory element in exon v6 (A) Potential miRNAs targeting CD44v6 predicted by miRNA-target prediction programs (miRwalk and RNAhybrid). (B) Potential MREs in exon v6 of CD44v6 mRNA. Top, schematic representation of three putative MREs in exon 6; bottom, the sequences of four potential MREs. (C) Schematic representation of synonymous mutations (Mut1) and deletion (Mut2) at the putative MREs. (D) Luciferase reporter assays in HEK293 cells, indicating that miR-193b-5p targets CD44v6 in MRE1. (E) Western blot (left) or qRT-PCR analysis of CD44v6 expression (right) in Hs-578t and BT-549 cells transfected with miR-193b-5p mimic, *P<0.05; **P<0.01;***P<0.001, P=ns. ns, no significance. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31892992), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Flow Cytometry

Detection of CD44 by Flow Cytometry

miR-205-5p LNA inhibition reduces the stem-like phenotype of BCSCs.a FACS analysis of CD24, CD44 and CD44v6 expression of BCSCs#3 after 24 h of treatment with 120 pmol of miRCURY LNA miR-205-5p inhibitor (LNA-i-miR-205-5p: blue line) or the scramble control (scr: red line) (upper panel). Data are presented as mean ± SD with T-test analysis of the percentage fold over control of receptors expression in three different experiments (lower panel). b Real-time PCR of CD24, CD44, CD44v6 and CD49f receptors of BCSCs#3 treated for 24 h as described above. Data are presented as mean ± SD with T-test analysis. c Representative FACS analysis of ALDH1 activity of BCSCs after 24 h of treatment with 120 pmol of LNA miR-205-5p inhibitor or the scramble control using Aldefluor Assay. Histograms (lower panel) show the mean ± SD with T-test analysis of the percentage fold over control of ALDH activity in two different experiments. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41419-018-0854-9), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

CD44v6 expression is associated with the migration and invasion of breast cancer. (A) Expression of CD44v6 in the breast cancer cell lines MCF-7, T-47D, Hs-578t, and BT-549. Left, western blot analysis of CD44v6 protein; Right, qRT-PCR analysis of CD44v6 mRNA levels.(B) Immunoblot analysis of CD44v6 expression in Hs-578t and BT-549 cells transfected with CD44v6 siRNA. (C-D) Migration (left, wound healing) and invasion (right, transwell) assays for control and CD44v6 knockdown Hs-578t (upper panel) and BT-549 (bottom panel) cells. Quantitative results of migratory cells are shown. Data show the mean±SD of three independent experiments. **P<0.01;***P<0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31892992), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Immunohistochemistry

Detection of CD44 by Immunohistochemistry

Immunohistochemistry of candidate biomarkers in prostate cancer. Representative immunohistochemical staining of ACPP, ADAM9, ALDH1A2, CASR, CCND1, CCPG1, CD34, CD44, CD44v6, CHGA, CHMP1A, EI24, ENO2, GADD45B, HA, HAS2, HES6, HMMR, HOXC6, HYAL1, IGF1, IQCK, MAP4K4, MKI67, PAGE4, PLIN2, PTEN, SIAH2, SMAD4, SOX9, SPP1, SYP, and TP53 from prostate cancer tissue microarrays. Scale bar represents 50 μm. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24708576), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Immunohistochemistry

Detection of CD44 by Immunohistochemistry

CD44v6 and EGFR co-expression reduces DFI in tamoxifen-treated ER+ breast cancers. CD44v6 expression was determined in a TMA series (n = 140) of ER+ breast cancer patients that had received tamoxifen and for whom their EGFR status was known. (A) Representative images of high (H-score >47) and low (H-score <47) CD44v6 staining in TMAs and the associated frequency of the four possible phenotypes encountered in this TMA series. (B) Kaplan–Meier survival plots for the four possible phenotypes demonstrating that co-expression of CD44v6 and EGFR (or lack of both) were associated with the poorest DFI. (C) Cox regression analysis suggested the CD44v6+/EGFR+ phenotype to be more associated with poorer outcome versus grade although this was not significant. Image collected and cropped by CiteAb from the following open publication (http://journal.frontiersin.org/Article/10.3389/fonc.2016.00145/abstract), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

CD44v6 suppression reduces the invasive behavior of endocrine-resistant breast cancer cells. (A,B) siRNA suppression reduced CD44v6 expression in Tam-R and Fas-R cells without altering the expression of other CD44 variant isoforms. CD44v6 suppression in Tam-R cells reduced their invasive (C) and proliferative (D) capacity and enhanced their migration (E) whereas modest suppression of proliferation and migration was seen in Fas-R cells. (F) Western blotting analysis revealed that CD44v6 suppression reduced EGFR pathway component activity in Tam-R cells and suppressed Met and AKT signaling in Fas-R cells but did not alter total protein levels (F). Image collected and cropped by CiteAb from the following open publication (http://journal.frontiersin.org/Article/10.3389/fonc.2016.00145/abstract), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Flow Cytometry

Detection of CD44 by Flow Cytometry

miR-205-5p contributes to control BCSCs surface markers.a mRNA expression levels of miR205-5p, CD24, CD44, CD44v6 and CD49f in BCSCs #3 infected with miR-205-5p silencing lentivector (shmiR-205-5p) or with the empty vector analyzed by quantitative real-time PCR (qRT-PCR). Data are presented as mean ± SD with T-test analysis of three independent experiments. b Representative FACS analysis of CD24, CD44 and CD44v6 receptors expression of GFP-positive (infected) BCSC#3 cells infected with miR-205-5p silencing lentivector (shmiR: blue line) or with the empty vector (ctr: red line) (upper panel). Histograms (lower panel) show the mean ± SD with T-test analysis of the percentage fold over control of receptors expression in two different experiments. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41419-018-0854-9), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

RTP cells were phenotypic plastic and tumorigenic independent of stemness. A,B) Scheme illustrating that giant (G6) and normal‐sized cells (N6) were isolated from 8Gy‐irradiated HCT116 on day 6 by mesh filtering. A) Potentials of soft agar colony formation were compared between G6 and N6. (Left panel) shown are typical images of colonies formed. Scale bars, 250 µm. Number of colonies and surface of colonies were analyzed in middle and right panel, respectively. Mean ± SEM; Student's t test. B) Giant cell (yellow triangle) could be found in colonies formed from single N6 cells. Scale bars, 100 µm. C) Heat map of gene signatures expressed in 8Gy‐induced G6 and N6 versus unirradiated (NC) cell samples. N = 2 for each group. D) CD133 and CD44 expression in unsorted (Mix) cells on day 6 following 8 Gy, G6, N6, and NC cells detected by cytometry analysis. E) Expression of cancer stem cell markers in Mix, G6, N6, and NC cells detected by western blot. F) Diagram of the in vivo limited dilution assays (LDA). G,H) Diagram of the simplified LDA assay. Comparison of cancer stem cell (CSC) frequency among G6, N6, and NC cells. t‐test of G6 versus NC and N6 versus NC are indicated. I) Representative immunohistochemistry pictures displaying the presence of metastasis in the lung tissue formed by G6, N6, and Mix. Scale bar, 200 mm. Right panels: numbers of lung metastasis foci (>50 pan Actin‐positive cells) were counted. Mean ± SEM; One‐way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36658726), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of CD44 by Western Blot

Detection of CD44 by Western Blot

Overexpression of CD44v6, but not CD44v3, in MCF-7 cells promotes an invasive phenotype. (A) Transfection of MCF-7 cells with CD44v3 or CD44v6 resulted in expression of these proteins to a similar extent as seen in the Tam-R and Fas-R cells but did not alter the expression of other CD44 variants. (B) Overexpression of CD44v6 resulted in a gain of invasive capacity in MCF-7 cells, in contrast to CD44v3 overexpression that reduced the migratory (C) and proliferative (D) capacity of these cells. MCF-7 cells overexpressing CD44 isoforms were exposed to tamoxifen or fulvestrant for 7 days and their growth determined by cell counting. (E) CD44v6-overexpressing MCF-7 cells exhibited a reduced response to fulvestrant, but not tamoxifen, compared to the control or CD44v3-overexpressing cells. Image collected and cropped by CiteAb from the following open publication (http://journal.frontiersin.org/Article/10.3389/fonc.2016.00145/abstract), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human CD44 v6 Antibody (2F10)

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/106 cells
Sample: Human peripheral blood monocytes

Immunocytochemistry

8-25 µg/mL
Sample: Immersion fixed A431 human epithelial carcinoma cell line

Immunohistochemistry

1-25 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human colon adenocarcinoma tissue

Immunoprecipitation

Fox, S.B. et al. (1994) Cancer Res. 54:4539.

Western Blot

1 µg/mL
Sample: Recombinant Human CD44 v3-10

Reviewed Applications

Read 1 review rated 5 using BBA13 in the following applications:

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Protein A or G purified from ascites

Reconstitution

Sterile PBS to a final concentration of 0.5 mg/mL.


Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CD44

CD44 is a ubiquitously expressed protein that is the major receptor for hyaluronan and exerts control over cell growth and migration (1‑3). Human CD44 has a 20 amino acid (aa) signal sequence, an extracellular domain (ECD) with a 100 aa hyaluronan‑binding disulfide‑stabilized link region and a 325‑530 aa stem region, a 21 aa transmembrane domain, and a 72 aa cytoplasmic domain. Within the stem, ten variably spliced exons (v1‑10, exons 6‑15) produce multiple protein isoforms (1‑3). The standard or hematopoietic form, CD44H, does not include the variable segments (1‑3). Cancer aggressiveness and T cell activation have been correlated with expression of specific isoforms (1, 3). CD44v6 contains exon 10 and is associated with tumor progression and metastasis in many types of cancer including breast, colon, lung, renal, skin, and ovarian tumors. With variable N‑ and O‑glycosylation and splicing within the stalk, CD44 can range from 80 to 200 kDa (1). Within the N‑terminal invariant portion of the ECD (aa 21‑220), human CD44 shares 76%, 76%, 86%, 83% and 79% identity with corresponding mouse, rat, equine, canine and bovine CD44, respectively. The many reported functions of CD44 fall within three categories (1). First, CD44 binds hyaluronan and other ligands within the extracellular matrix and can function as a “platform” for growth factors and metalloproteinases. Second, CD44 can function as a co‑receptor that modifies activity of receptors including MET and the ERBB family of tyrosine kinases. Third, the CD44 intracellular domain links the plasma membrane to the actin cytoskeleton via the ERM proteins, ezrin, radixin and moesin. CD44 can be synthesized in a soluble form (4) or may be cleaved at multiple sites by either membrane‑type matrix metalloproteinases, or ADAM proteases to produce soluble ectodomains (5, 6). The cellular portion may then undergo gamma secretase‑dependent intramembrane cleavage to form an A beta ‑like transmembrane portion and a cytoplasmic signaling portion that affects gene expression (7, 8). These cleavage events are thought to promote metastasis by enhancing tumor cell motility and growth (1, 5).

References

  1. Ponta, H. et al. (2003) Nat. Rev. Mol. Cell Biol. 4:33.
  2. Screaton, G.R. et al. (1992) Proc. Natl. Acad. Sci. USA 89:12160.
  3. Lynch, K.W. (2004) Nat. Rev. Immunol. 4:931.
  4. Yu, Q. and B.P. Toole (1996) J. Biol. Chem. 271:20603.
  5. Nagano, O. and H. Saya (2004) Cancer Sci. 95:930.
  6. Nakamura, H. et al. (2004) Cancer Res. 64:876.
  7. Murakami, D. et al. (2003) Oncogene 22:1511.
  8. Lammich, S. et al. (2002) J. Biol. Chem. 277:44754.
  9. Fox, S.B. et al. (1994) Cancer Res. 54:4539.

Alternate Names

CD44, ECMR-III, HCAM, HCELL, LHR, MDU2, MDU3, MIC4, MUTCH-I, Pgp1

Entrez Gene IDs

960 (Human); 12505 (Mouse); 25406 (Rat); 100126860 (Porcine)

Gene Symbol

CD44

Additional CD44 Products

Product Documents for Human CD44 v6 Antibody (2F10)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.


Can't find your language? Request a SDS in your language here.

Product Specific Notices for Human CD44 v6 Antibody (2F10)

For research use only

Citations for Human CD44 v6 Antibody (2F10)

Customer Reviews for Human CD44 v6 Antibody (2F10) (1)

5 out of 5
1 Customer Rating
5 Stars
100%
4 Stars
0%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Human CD44 v6 Antibody (2F10)?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card
Showing  1 - 1 of 1 review Showing All
Filter By:
  • Human CD44v6 Antibody
    Name: Anonymous
    Application: ELISA
    Sample Tested: EDTA Plasma
    Species: Human
    Verified Customer | Posted 11/08/2018

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies